This filing reveals a severe internal control failure and potential fraud at the CFO level, directly causing a late 10-K filing. For a micro-cap OTC stock, this creates material going-concern and delisting risk. Monitor for the late 10-K filing (NT 10-K), any auditor resignation (Item 4.01), and the outcome of the litigation. The stock is likely to face selling pressure and impaired access to capital.
Price Chart
Executive Summary
Regenerex Pharma filed an 8-K disclosing that it has commenced litigation against its former CFO, Kenneth W. Perry, alleging unauthorized payroll overpayments of approximately $55,200, self-dealing via a vendor he controlled (overcharges of ~$37,285), unauthorized stock issuances of 25,000 shares to a family trust, destruction of accounting records, and coercive conduct. The company states it was unable to timely file its Form 10-K as a direct result of Perry's actions. This is a material governance and financial reporting crisis for a micro-cap OTC stock.
Key Facts
- Former CFO Kenneth W. Perry allegedly caused unauthorized payroll overpayments of ~$55,200 over 6 months.
- Perry allegedly self-dealt through Optimize Health Partners, LLC, overcharging Regenerex ~$37,285 via a 30% administrative fee.
- Perry allegedly authorized 25,000 shares of common stock to a family trust without board approval.
- The company alleges Perry intentionally deleted, altered, and corrupted accounting records, impairing the year-end audit.
- Regenerex states it was unable to timely file its Form 10-K as a direct result of Perry's conduct.
- The company is seeking monetary damages, restitution, and injunctive relief in Smith County Chancery Court (Case No. 2026-CV-8818).
Financial Impact
Quantified unauthorized payments total at least $92,485 ($55,200 payroll overpayments + $37,285 vendor overcharges), plus unquantified costs for forensic accounting, legal fees, audit delays, and potential SEC penalties. The company's inability to file its 10-K on time creates risk of trading interruption and loss of financing.
Risk Factors
- Inability to file Form 10-K on time may lead to SEC enforcement, trading suspension, or OTC delisting.
- Potential for additional undiscovered unauthorized transactions or financial misstatements.
- Litigation costs and management distraction could further strain limited resources.
- Risk of auditor resignation or going-concern qualification in the delayed 10-K.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001472375-26-000167 |
| Document: ixform8k.htm | 0001472375-26-000167 |
| Document: 0001472375-26-000167-index-headers.html | 0001472375-26-000167 |
| Document: 0001472375-26-000167-index.html | 0001472375-26-000167 |
| Document: 0001472375-26-000167.txt | 0001472375-26-000167 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 4, 2026 7w ago | 8-K | — | awaiting T+20 | — | — |
Sep 1, 2026 7w ago | 8-K | — | awaiting T+20 | — | — |
Jun 11, 2026 19w ago | 8-K | — | awaiting T+20 | — | — |
May 6, 2026 24w ago | 8-K | — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers